TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, Louis Mauriac, Pierre Fumoleau, Etienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Cufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David A Cameron, Jonas BerghRichard Iggo, EORTC 10994/BIG 1-00 Study Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.
Original languageEnglish
Pages (from-to)527-39
Number of pages13
JournalThe Lancet Oncology
Volume12
Issue number6
DOIs
Publication statusPublished - 2011

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Female
  • Humans
  • Middle Aged
  • Mutation
  • Neoadjuvant Therapy
  • Receptor, erbB-2
  • Receptors, Estrogen
  • Taxoids
  • Tumor Suppressor Protein p53

Fingerprint Dive into the research topics of 'TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial'. Together they form a unique fingerprint.

Cite this